HYDRATE WELLNESS

Research Articles

1. Al Tameemi W, Dale TP, Al-Jumaily RMK, Forsyth NR. Hypoxia-modified cancer cell metabolism. Front Cell Dev Biol. 2019;7:4.

PubMed – PubMed Central – Article – Google Scholar Mennerich D, Kubaichuk K, Kietzmann T. DUBs, Hypoxia, and Cancer. Trends Cancer. 2019;5(10):632–53. CAS – PubMed – Article – Google Scholar

2. Bento CF, Pereira P. Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes. Diabetologia. 2011;54:1946–56.

CAS– PubMed – Article – Google Scholar 

3. Wang J, Ni Z, Duan Z, Wang G, Li F. Altered expression of hypoxia-inducible factor-1α (HIF-1α) and its regulatory genes in gastric cancer tissues. PloS ONE. 2014;9:e99835.

PubMed – PubMed Central – Article – CAS – Google Scholar

4. Baumann RP, Penketh PG, Seow HA, Shyam K, Sartorelli AC: Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cells. Radiat Res. 2008, 170 (5): 651-660. 10.1667/RR1431.1.

CAS – Article – PubMed PubMed Central – Google Scholar

5. Zhang Z, Yao L, Yang J, Wang Z, Du G. PI3K/Akt and HIF-1 signaling pathway in hypoxia-ischemia. Mol Med Rep. 2018;18:3547–54.

CAS – PubMed – PubMed Central – Google Scholar

6. Al Qahtani A, Holly J, Perks C. Hypoxia negates hyperglycemia-induced chemo-resistance in breast cancer cells: the role of insulin-like growth factor binding protein 2. Oncotarget. 2017;8:74635–48.

PubMed – PubMed Central – Article – Google Scholar

7. Joan Khoo, Christoph E. Hagemeyer, Darren C. Henstridge. Effects of water stably-enriched with oxygen as a novel method of tissue oxygenation on mitochondrial function, and as adjuvant therapy for type 2 diabetes in a randomized placebo controlled trial. 2021, 0254619

PlosONE

8. Görgens SW, Benninghoff T, Eckardt K, Springer C, Chadt A, Melior A, et al. Hypoxia in combination with muscle contraction improves insulin action and glucose metabolism in human skeletal muscle via the HIF-1α pathway. Diabetes. 2017;66:2800–7.

PubMed – Article – CAS – PubMed Central – Google Scholar

9. Triner D, Shah YM. Hypoxia-inducible factors: a central link between inflammation and cancer. J Clin Invest. 2016;126:3689–98.

PubMed – PubMed Central – Article – Google Scholar

10. Han S, Huang T, Hou F, Yao L, Wang X, Wu X. The prognostic value of hypoxia-inducible factor-1α in advanced cancer survivors: a meta-analysis withtrial sequential analysis. Ther Adv Med Oncol. 2019;11:1758835919875854

CAS – PubMed – PubMed Central – Google Scholar

11. Krutilina R, Sun W, Sethuraman A, Brown M, Seagroves TN, Pfeffer LM, et al. MicroRNA-18a inhibits hypoxia inducible factor 1α activity and lung metastasis in basal breast cancers. Breast Cancer Res. 2014;16:R78.

PubMed – PubMed Central – Article – CAS – Google Scholar

12. Rohwer N, Cramer T: Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011, 14 (3): 191-201. 10.1016/j.drup.2011.03.001.

CAS – Article – PubMed – Google Scholar

13. García-Pastor C, Benito-Martínez S, Moreno-Manzano V, Fernández-Martínez AB, Lucio-Cazaña FJ. Mechanism and consequences of the impaired Hif-1α response to hypoxia in human proximal tubular HK-2 cells exposed to high glucose. Sci Rep. 2019;9:15868.

PubMed – PubMed Central – Article – CAS – Google Scholar

14. Rohwer N, Dame C, Haugstetter A, Wiedenmann B, Detjen K, Schmitt CA, Cramer T: Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One. 2010, 5 (8): e12038-10.1371/journal.pone.0012038.

Article – PubMed – PubMed Central – Google Scholar

15. Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB,

16. Choyke P, Murgo AJ, Doroshow JH, Melillo G: Multihistology, 2005 ; target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors. Clin Cancer Res. Rev. 2011, 17(15):5123–5 10.1158/1078-0432.CCR-11-0682. CAS – Article – PubMed – PubMed Central – Google Scholar

17. Partridge SE, Aquino-Parsons C, Luo C, Green A, Olive PL: A pilot study comparing intratumoral oxygenation using the comet assay following 2.5% and 5% carbogen and 100% oxygen. Int J Radiat Oncol Biol Phys. 2001, 49 (2): 575-580. 10.1016/S0360-3016(00)01504-2. CAS – Article – PubMed – Google Scholar
18. Evans SM, Hahn SM, Magarelli DP, Koch CJ: Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol. 2001, 24 (5): 467-472. 10.1097/00000421-200110000-00011. CAS – Article – PubMed – Google Scholar

19. Brahimi-Horn MC, Chiche J, Pouyssegur J: Hypoxia and cancer. J Mol Med. 2007, 85 (12): 1301-1307. 10.1007/s00109-007-0281-
Article – PubMed – Google Scholar

20. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009, 324 (5930): 1029-1033. 10.1126/science.1160809. CAS – Article – PubMed PubMed Central – Google Scholar
21. Brown JM, Wilson WR: Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer. 2004, 4 (6): 437-447. 10.1038/nrc1367. CAS – Article – PubMed – Google Scholar

22. Wartenberg M, Ling FC, Muschen M, Klein F, Acker H, Gassmann M, Petrat K, Putz V, Hescheler J, Sauer H: Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species.FASEB J. 2003, 17 (3): 503-505.CAS – PubMed – Google Scholar

23. Matzow T, Cowen RL, Williams KJ, Telfer BA, Flint PJ, Southgate TD, Saunders MP: Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumor sensitivity to irinotecan (CPT-11). J Gene Med. 2007, 9 (4): 244-252. 10.1002/jgm.1016. CAS – Article – PubMed – Google Scholar
24. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, Dive C: Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol. 2004, 24 (7): 2875-2889. 10.1128/MCB.24.7.2875-2889.2004. CAS – Article – PubMed – PubMed Central – Google Scholar
25. Kim JY, Kim YJ, Lee S, Park JH: The critical role of ERK in death resistance and invasiveness of hypoxia-selected glioblastoma cells.BMC Cancer. 2009, 9: 27-10.1186/1471-2407-9-27. Article – PubMed – PubMed Central – Google Scholar
26. Minchinton AI, Tannock IF: Drug penetration in solid tumors. Nat Rev Cancer. 2006, 6 (8): 583-592. 10.1038/nrc1893. CAS – Article – PubMed – Google Scholar Minchinton AI, Tannock IF:
27. Hay MP, Gamage SA, Kovacs MS, Pruijn FB, Anderson RF, Patterson AV, Wilson WR, Brown JM, Denny WA: Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J Med Chem. 2003, 46 (1): 169-182. 10.1021/jm020367+ CAS – Article – PubMed – Google Scholar
28. Shin DH, Chun YS, Lee DS, Huang LE, Park JW: Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood. 2008, 111 (6): 3131-3136. 10.1182/blood-2007-11-120576. CAS – Article – PubMed –Google Scholar
29. Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E: Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. Biochem Pharmacol. 2007, 74 (2): 191-201. 10.1016/j.bcp.2007.04.003. CAS – Article – PubMed – Google Scholar
30. Escuin D, Kline ER, Giannakakou P: Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res. 2005, 65 (19): 9021-9028. 10.1158/0008-5472.CAN-04-4095. CAS – Article – PubMed – Google Scholar
31. Forde JC, Perry AS, Brennan K, Martin LM, Lawler MP, Lynch TH, Hollywood D, Marignol L: Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells. Urol Oncol. 2010, 30: 912-919. Article – PubMed – Google Scholar
32. Sermeus A, Cosse JP, Crespin M, Mainfroid V, de Longueville F, Ninane N, Raes M, Remacle J, Michiels C: Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity. Mol Cancer. 2008, 7: 27- Article – PubMed – PubMed Central – Google Scholar
33. Sullivan R, Graham CH: Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol Cancer Ther. 2009, 8 (6): 1702-1713. 10.1158/1535-7163.MCT-08-1090. CAS – Article – PubMed – Google Scholar

HYDRATE Wellness

COMPANY

LEARN MORE

INQUIRES

FOLOW US ON

Youtube Pinterest Instagram Facebook-f

SUSCRIBE TO OUR EMAIL

Copyright 2024., Hydrate Spa Inc.

Scroll to Top